Axonlab is now a distributor for spinit® in six European countries. biosurfit continues to build a strong commercial presence in more than twenty countries

 

Lisbon, Portugal, 27th June 2017 – biosurfit SA (“biosurfit”), the in vitro point-of-care (PoC) diagnostics company, announces that it has signed a distribution agreement with Axon Lab AG (“Axonlab”) for the commercialisation of its spinit® point-of-care instrument in Switzerland. spinit® offers a comprehensive menu of fast, easy to perform laboratory quality tests in a point-of-care instrument, including HbA1c (Haemoglobin A1c), CRP (c-reactive protein) and BC (blood count).
 

This is the sixth national distribution agreement biosurfit has signed with Axonlab, an independent European distribution, services and production company focusing on medical diagnostics, life science and software solutions for the healthcare sector. Under the terms of these agreements, biosurfit has granted Axonlab the rights to promote, market, and sell the spinit® instrument and associated discs to hospitals, doctors, clinics, private laboratories and research institutions in Austria, Croatia, Slovakia, the Czech Republic, Slovenia and now Switzerland.

 

Axonlab has dedicated diagnostics franchises and direct offices in each of the countries covered under the agreements and is well positioned to accelerate the commercial launch of spinit® in Switzerland and the Central and Eastern European markets. biosurfit will continue its direct sales programs in its home market of Portugal.

 

“We are excited to partner with biosurfit for the commercial distribution of the spinit® instrument and test discs in several of our core markets in Europe,”, said Roland Steger, CEO of Axonlab. “spinit® unique technology and attractive menu of tests, on a rapid and simple to use instrument, will allow these key tests to be performed in doctors’ offices, clinics, and other testing sites at the point-of-care. Our collaboration with biosurfit is expected to be another driver for our future growth at Axonlab in the years ahead.”

 

João Garcia da Fonseca, CEO of biosurfit, commented: “We are pleased to expand our partnership with Axonlab, whose track record has shown that they are the right partner for us in these markets. Now with the addition of Switzerland, the Axonlab collaboration adds several important markets to our distribution portfolio and will allow us to accelerate the commercial roll-out of spinit®”.

 

“biosurfit has already has a strong commercial presence, either directly or through our distribution partners, and we plan to continue expanding this worldwide network through the addition of new commercial partnerships.”

 
Enquiries
biosurfit SA
João Garcia da Fonseca, Chief Executive Officer
Daniel Neves, Chief Marketing Officer
+351 218 860 169
 
FTI Consulting (media relations)
Simon Conway / Natalie Garland-Collins
Tel: +44 (0)203 727 1000

 
Notes to editors
 

About biosurfit and spinit®

biosurfit is a fast-growing and highly innovative commercial stage European medical diagnostics company focused on the development and manufacture of breakthrough technologies for the in vitro diagnostic (IVD) market. Its lead product spinit®, which was commercially launched in 2014, addresses an unmet need for fast, precise, reliable, easy-to-use blood analysis for medical testing in the point-of-care setting.

 

About Axonlab

Axonlab is a cutting-edge, customer-oriented service company operating in the fields of medical diagnostics, life science and software solutions for the health-care sector. Since 1990 Axonlab has collaborated with reputable international supply partners in selling innovative systems to clinics, doctors and the research sector. Axonlab focuses on providing a comprehensive, future-oriented service, to provide a foundation for long-term business relations.